Insmed, Inc. (INSM)
118.34
-3.05
(-2.51%)
USD |
NASDAQ |
Aug 28, 15:42
Insmed Cash from Operations (Quarterly) : -88.83M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -88.83M |
| March 31, 2026 | -222.74M |
| December 31, 2025 | -247.60M |
| September 30, 2025 | -219.76M |
| June 30, 2025 | -205.57M |
| March 31, 2025 | -262.09M |
| December 31, 2024 | -195.98M |
| September 30, 2024 | -180.92M |
| June 30, 2024 | -122.95M |
| March 31, 2024 | -184.04M |
| December 31, 2023 | -129.60M |
| September 30, 2023 | -136.33M |
| June 30, 2023 | -122.79M |
| March 31, 2023 | -147.52M |
| December 31, 2022 | -103.15M |
| September 30, 2022 | -89.83M |
| June 30, 2022 | -102.30M |
| March 31, 2022 | -105.16M |
| December 31, 2021 | -84.13M |
| September 30, 2021 | -75.44M |
| June 30, 2021 | -75.44M |
| March 31, 2021 | -128.28M |
| December 31, 2020 | -66.79M |
| September 30, 2020 | -58.67M |
| June 30, 2020 | -35.95M |
| Date | Value |
|---|---|
| March 31, 2020 | -57.94M |
| December 31, 2019 | -44.40M |
| September 30, 2019 | -52.37M |
| June 30, 2019 | -80.03M |
| March 31, 2019 | -73.85M |
| December 31, 2018 | -69.54M |
| September 30, 2018 | -65.49M |
| June 30, 2018 | -54.91M |
| March 31, 2018 | -68.04M |
| December 31, 2017 | -48.22M |
| September 30, 2017 | -38.24M |
| June 30, 2017 | -36.25M |
| March 31, 2017 | -36.91M |
| December 31, 2016 | -57.96M |
| September 30, 2016 | -30.98M |
| June 30, 2016 | -28.24M |
| March 31, 2016 | -29.53M |
| December 31, 2015 | -27.55M |
| September 30, 2015 | -24.03M |
| June 30, 2015 | -24.24M |
| March 31, 2015 | -24.88M |
| December 31, 2014 | -12.93M |
| September 30, 2014 | -20.90M |
| June 30, 2014 | -17.93M |
| March 31, 2014 | -12.65M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| United Therapeutics Corp. | 310.20M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Biogen, Inc. | 448.90M |
| Gilead Sciences, Inc. | 3.573B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 24.51M |
| Cash from Financing (Quarterly) | 27.18M |
| Free Cash Flow | -837.67M |
| Free Cash Flow Per Share (Quarterly) | -0.4375 |
| Free Cash Flow to Equity (Quarterly) | -93.93M |
| Free Cash Flow to Firm (Quarterly) | -71.48M |
| Free Cash Flow Yield | -3.30% |